about
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcomeEx vivo identification and characterization of a population of CD13(high) CD105(+) CD45(-) mesenchymal stem cells in human bone marrow.Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.Current state of biology and diagnosis of clonal mast cell diseases in adults.Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool.Anaphylaxis as a clinical manifestation of clonal mast cell disorders.The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis.Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.Insights in Anaphylaxis and Clonal Mast Cell Disorders.Management of Anesthesia in Adult and Pediatric Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) Based on 726 Anesthetic Procedures.Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis.Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations.Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis.Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis.Characterization of CD34+ hematopoietic cells in systemic mastocytosis: potential role in disease dissemination.CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis.An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.Evaluation of the WHO criteria for the classification of patients with mastocytosis.Systemic mastocytosis presenting as occupational IgE-mediated anaphylaxis to pine processionary caterpillar.Tryptase increase on the first day of hymenoptera venom immunotherapy might be a predictor of future systemic reactions during treatment.Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis.Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion.KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression.Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients.Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.Contribution of highly sensitive diagnostic methods to the diagnosis of systemic mastocytosis in the absence of skin lesionsMast cell-related disorders presenting with Kounis syndromeBone Marrow Expression of Mast Cell DisordersBone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic MastocytosisPrevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 casesFulminant necrotizing fasciitis caused by Serratia marcescens in an immunosuppressed host
P50
Q33158687-79251A4F-BD2B-42D8-8E53-018DC0FDC084Q34987900-3FCF16F3-34B6-49AE-A71A-CD965940C6C6Q35025246-3A9A69A0-CE19-4969-B51A-E50A708A5771Q36034814-8D733DDC-12D8-466A-9031-91FC4F34D212Q37873485-0988C93F-1C66-4114-A80F-9D7D4A75CE9BQ38007005-2CBD961B-E115-4BC8-8D0E-822128C9D842Q38205501-F05E840E-4362-4E99-AE38-61346D372382Q38221739-5A4C72B5-992C-435E-B8D0-9B28678C6610Q38266219-FF3C61D0-ED14-4827-B212-47A777CA1F19Q38609927-EC83B5E2-234E-426D-A173-CAA897ACA643Q39455752-DAB5D2C4-6CBE-4CB7-9232-20F057F97F6AQ41599066-9EDEA314-760B-485A-B523-14FAA0D19B95Q41604021-17C2B0C0-1C00-49BD-A330-B58F550169EEQ42459109-DBA03EDD-F68B-4995-840D-73D788C5D647Q44767953-46731188-5336-4F1C-BD5E-B51C33C7708DQ46029172-5A4719DB-C45A-4DCF-94CA-73655D4C6959Q46113086-264B79A1-4473-4F26-92E0-273A1B6753E2Q46687182-29D5996A-F08A-4056-A30E-6335245E5D85Q50056845-3F370864-E4D1-4C32-9A3D-3EAE441F18A4Q50484927-EE8440EC-183D-4C0D-A7EC-5527AD79B863Q50900052-0A1284B6-3082-4701-90E7-12AA7428502CQ51013817-BDDFFDDF-CDAC-41C1-8D30-EE46EC6E581FQ51505022-A496800B-CA0E-4130-AC14-71728ABA2278Q51571187-9A8874AD-C981-46E1-A031-09C14BF0842FQ51605724-C9B0F492-4808-4F41-B56C-58583555A5B0Q52626024-292DEB55-F5FD-479D-B373-B473EDF4E005Q52687592-12D0014A-FB09-4853-8BAE-5265DABF740CQ52700313-3426F07D-9486-4B19-B24A-DD647D1392D1Q52884801-7F81BEE0-E769-47E2-B0D0-509C7B513B89Q53093872-692D3973-1AFA-4348-B46C-F1BC9B47FA30Q53259178-49C28322-CA65-41BD-A331-437A32E09C9FQ53315532-C412BCBB-EE7A-4B4D-8EE2-F9A518FA1B4CQ54447022-6A8E8541-2CD4-45A6-8819-E9460CED59AEQ61313628-CCA45022-B6E4-4762-9B0D-C049DCBC60D5Q61818962-D566C8D5-0669-4F2A-B949-FDAC45375C27Q64044396-932CC617-85DB-4B5F-8DDD-C279A370E830Q64277635-AB9DD9DD-89DB-4FDB-88F3-CCDDE4A4B1D6Q81329279-57A698EF-2B2E-4346-92F6-5751124154E4Q83743977-4F23D740-64C4-4F3A-970B-69A1E9BF8738Q84233254-92746CFC-EE91-4CE0-986F-28698465BA53
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Iván Alvarez-Twose
@en
Iván Alvarez-Twose
@nl
type
label
Iván Alvarez-Twose
@en
Iván Alvarez-Twose
@nl
prefLabel
Iván Alvarez-Twose
@en
Iván Alvarez-Twose
@nl
P31
P496
0000-0002-1190-4473